U.S. Hotel and Resort REITs Stock News

NYSE:ZETA
NYSE:ZETASoftware

Is Zeta Global (ZETA) Recasting Its Investor Narrative With a Veteran IR Leader at the Helm?

Zeta Global announced that Trey Campbell became Senior Vice President of Investor Relations on July 27, 2026, succeeding Matt Pfau as he moved into the Senior Vice President, Financial Planning & Analysis role. Campbell’s long tenure in technology finance and investor relations at Synopsys, Luminar Technologies, and Intel brings deep capital-markets experience to how Zeta communicates its performance and long-term ambitions. Next, we’ll consider how bringing in a veteran investor relations...
NasdaqGS:PCRX
NasdaqGS:PCRXPharmaceuticals

Pacira BioSciences (PCRX) Advances PCRX 201 As Its Undervalued Narrative Faces A Fresh Test

Pacira BioSciences (PCRX) has advanced PCRX-201, its osteoarthritis gene therapy candidate, to a scalable U.S. commercial manufacturing process and has begun enrolling patients in Part B of the Phase 2 ASCEND study. See our latest analysis for Pacira BioSciences. The latest PCRX-201 update comes as Pacira BioSciences trades at US$26.92, with a 30 day share price return of 6.03% and a 90 day share price return of 13.63%. Over five years, the total shareholder return has declined 52.07%,...
NYSE:ESS
NYSE:ESSResidential REITs

Essex Property Trust (ESS) Cuts 2026 Guidance, Is The Stock Fully Priced?

Essex Property Trust (ESS) is back in focus after releasing second quarter 2026 results that paired higher revenue with a sharply lower net income figure and a trimmed full year earnings outlook. See our latest analysis for Essex Property Trust. Despite the softer second quarter and lowered 2026 earnings guidance, Essex Property Trust’s share price has a year to date share price return of 11.29% and a 1 year total shareholder return of 15.51%. This signals momentum that has cooled in recent...
NasdaqGS:STLD
NasdaqGS:STLDMetals and Mining

Steel Dynamics Stock And 2 Domestic Manufacturing Picks for Tariff Focused Investors

Tariffs are back in the headlines, with 25 states challenging the Trump administration’s latest round that touches nearly all U.S. imports from 59 countries and the EU. For U.S. Domestic Manufacturing Stocks, this legal and trade backdrop can change the balance between import heavy companies and those with a stronger local production base. Higher costs and supply chain friction may hurt some businesses and create openings for others. This article breaks down how that trade shock could matter...
NYSE:EVC
NYSE:EVCMedia

Entravision Communications (EVC) Pulls Back After A Strong Rebound, Is The Premium Already Too High?

Entravision Communications (EVC) has drawn investor attention after recent trading, with the stock down about 15% over the past month yet up roughly 44% in the past 3 months. See our latest analysis for Entravision Communications. Zooming out, Entravision Communications has seen short term momentum cool, with a 1 month share price return of about a 15% decline, while a very strong 1 year total shareholder return of around 413% points to powerful longer term gains. If you are looking for other...
NYSE:ARE
NYSE:AREHealth Care REITs

Is MAP-D Depression Research Progress And Mixed Q2 Results Altering The Investment Case For Alexandria Real Estate Equities (ARE)?

Alexandria Real Estate Equities, Inc. reported second-quarter 2026 revenue of US$662.78 million with a US$72.78 million net loss, while its six-month results showed revenue of US$1,333.81 million and net income of US$288.87 million, alongside progress on the MAP-D depression research initiative with the Foundation for the National Institutes of Health. The MAP-D collaboration, now through its critical design phase and moving toward a research effort expected to exceed US$70 million,...
NYSE:LLY
NYSE:LLYPharmaceuticals

Eli Lilly (LLY) Wins FDA Breakthrough Status For Olomorasib In Pancreatic Cancer

Eli Lilly (NYSE:LLY) received U.S. FDA Breakthrough Therapy designation for olomorasib. The designation covers olomorasib as a monotherapy in previously treated, KRAS G12C-mutant advanced pancreatic cancer. This mutation currently has no approved targeted therapies in pancreatic cancer. The decision marks a significant regulatory milestone in Lilly’s oncology pipeline. Eli Lilly has built strong investor attention around its diabetes and obesity treatments, and this new FDA designation...
NasdaqGS:BNTX
NasdaqGS:BNTXBiotechs

Deeper Losses And New CEO Could Be A Game Changer For BioNTech’s (BNTX) R&D Strategy

BioNTech SE has reported past second-quarter 2026 results showing sales of €105.6 million versus €260.8 million a year earlier, with net loss widening to €820.8 million and basic loss per share from continuing operations increasing to €3.24 from €1.60. At the same time, the Supervisory Board has moved to refresh leadership by appointing experienced biopharma executive Guido Oelkers as future CEO, a shift that could influence how BioNTech balances heavy R&D spending with efforts to broaden...
NasdaqGS:OPRA
NasdaqGS:OPRASoftware

Opera (OPRA) Could Be 26% Undervalued Following User Growth And $300 Million Buyback

Opera (NasdaqGS:OPRA) is back in focus after reporting 288 million monthly active users in the first quarter of 2026, a 25% rise in annualized average revenue per user, and approving a $300 million share repurchase program. See our latest analysis for Opera. At a share price of US$19.51, Opera has seen a 37.10% year to date share price return and a 26.35% total shareholder return over the past year. Multi year total shareholder returns above 100% suggest longer term holders have already...
NYSE:MOG.A
NYSE:MOG.AAerospace & Defense

Upgraded Sales Guidance And Bolt‑On M&A Focus Could Be A Game Changer For Moog (MOG.A)

In the third quarter and first nine months of fiscal 2026, Moog Inc. reported higher sales and net income, raised its full-year net sales guidance to US$4.40 billion, and its Board declared a US$0.30 quarterly dividend payable on August 25, 2026. Management also highlighted a lower 1.5x leverage ratio and a preference for bolt-on acquisitions, suggesting increased financial flexibility to expand Moog’s portfolio while maintaining a balanced capital deployment approach. We'll now examine how...
NYSE:WK
NYSE:WKSoftware

Workiva (WK) Launches New AI Agents As Its Undervalued Narrative Gains Attention

Workiva (WK) has just rolled out three AI agents and a new Workiva Knowledge layer that aim to cut manual work in financial reporting, compliance, and sustainability disclosures for enterprise customers. See our latest analysis for Workiva. The new AI agents arrive at a time when Workiva’s recent 30-day share price return of 17.85% and 90-day share price return of 18.77% contrast with a year-to-date share price decline of 26.24% and a 3-year total shareholder return decline of 42.69%. This...
NYSE:PNC
NYSE:PNCBanks

PNC Financial Services Group (PNC) Could Be 9% Undervalued After 50th New Branch Opening

PNC Financial Services Group (PNC) just crossed a key expansion milestone by opening its 50th new branch as part of a plan for more than 300 new locations and extensive renovations nationwide. See our latest analysis for PNC Financial Services Group. For context, PNC Financial Services Group’s recent expansion news follows a period of steady momentum, with a 90-day share price return of 13.17% and a 1-year total shareholder return of 37.58% on a share price of $251.72. If this kind of steady...
NasdaqGS:ALNY
NasdaqGS:ALNYBiotechs

Alnylam (ALNY) Turns Profitable as Revenue Mix Shifts: What Changes in Its Investment Story?

In the second quarter of 2026, Alnylam Pharmaceuticals reported revenue of US$1,290.95 million and net income of US$164.49 million, marking a shift from a loss a year earlier, and also showed much higher revenue and profitability for the first half of the year. Alongside these results, the company trimmed its full‑year net product revenue outlook while increasing expectations for collaboration and royalty revenue, highlighting a changing mix in how it generates sales. Next, we’ll examine how...
NYSE:NPO
NYSE:NPOMachinery

Enpro (NPO) Is Up 6.5% After Q2 Earnings Beat And Dividend Hike - Has The Bull Case Changed?

Enpro Inc. has released its second-quarter 2026 results, reporting sales of US$338.8 million and net income of US$27.1 million, alongside a quarterly dividend declaration of US$0.32 per share payable on September 16, 2026. The combination of continued revenue and earnings growth over both the quarter and first half of 2026 underscores management’s focus on expanding higher-value, resilient business lines. We’ll now examine how this latest quarter of revenue and earnings growth might...
NasdaqCM:PGY
NasdaqCM:PGYSoftware

Pagaya Technologies (PGY) Raised Guidance, Is The Stock Still A Bargain?

Pagaya Technologies (PGY) is in focus after reporting second quarter 2026 results that featured record network volumes and higher net income, followed by raised full year and third quarter guidance that has drawn fresh investor attention. See our latest analysis for Pagaya Technologies. The latest earnings release and higher guidance have coincided with a sharp rebound in Pagaya Technologies' stock, with a 7 day share price return of 33.87% and a 90 day share price return of 49.93%. However,...
NasdaqGM:TMDX
NasdaqGM:TMDXMedical Equipment

Do TransMedics’ (TMDX) New Equity Grants And UBS Coverage Reveal A Shifting Growth Playbook?

TransMedics Group, Inc. recently announced it will report its Q2 2026 financial results and host an earnings call after the market closes on August 4, 2026, while also granting stock options and restricted stock units to new employees under Nasdaq Listing Rule 5635(c)(4). Together with fresh UBS research coverage, these developments highlight how external analyst attention and internal talent incentives are shaping investor focus on TransMedics’ next phase of growth. With new UBS coverage...
NYSE:ATI
NYSE:ATIAerospace & Defense

Rising Earnings Estimates and Strong Returns Might Change The Case For Investing In ATI (ATI)

In recent months, ATI, ranked #2 (Buy) by Zacks in the aerospace sector, has seen analysts lift their full‑year earnings estimates by 2.3%, reflecting stronger sentiment toward its earnings outlook. This upgrade in expectations, alongside ATI’s year‑to‑date return of 63.3% that exceeds sector and industry averages, underscores how rapidly investor confidence has consolidated around the company’s role in aerospace materials. We’ll now examine how this upward shift in earnings expectations may...
NYSE:SMR
NYSE:SMRElectrical

NuScale Power (SMR) Heads Into Earnings With Project Updates Putting Valuation Back In Focus

NuScale Power (SMR) is in focus ahead of its second quarter 2026 earnings release on August 5, as investors watch for concrete updates on the Tennessee Valley Authority discussions and Romania’s RoPower project. See our latest analysis for NuScale Power. NuScale Power’s recent price action has been volatile, with a 7.01% 1 day share price return and 9.61% 7 day share price return, yet the 1 year total shareholder return has fallen 80.04%. This highlights building short term momentum against a...
NYSE:IIPR
NYSE:IIPRIndustrial REITs

Is Innovative Industrial Properties (IIPR) A Bargain After Q2 Results And Buyback?

Innovative Industrial Properties (IIPR) just reported its second quarter 2026 results alongside an update on its completed share repurchase program, providing new information on profitability, revenue and capital returns to shareholders. See our latest analysis for Innovative Industrial Properties. At a share price of US$58.59, Innovative Industrial Properties has seen a 30 day share price return that is down 7.53%, even though the year to date share price return is up 18.44% and the 1 year...
NasdaqGM:APPF
NasdaqGM:APPFSoftware

Is AppFolio (APPF) A Bargain As Earnings And Guidance Lift Its Valuation Debate?

AppFolio (APPF) is back in focus after its latest quarterly update, which combined second quarter 2026 earnings, fresh full year revenue guidance, and an update on its completed share repurchase program. See our latest analysis for AppFolio. The upbeat quarterly release and higher full year revenue outlook have come alongside a sharp rebound in sentiment, with a 14.67% 90 day share price return and 12.16% 30 day share price return. However, the total shareholder return is still down 38.89%...
NYSE:DAC
NYSE:DACShipping

Earnings Beat And Margin Strength Could Be A Game Changer For Danaos (DAC)

Danaos Corporation has reported past second-quarter 2026 results showing sales of US$274.37 million and net income of US$151.82 million, with both basic and diluted earnings per share from continuing operations higher than a year earlier. The combination of rising sales and expanding earnings for both the quarter and first half of 2026 underscores resilient operating performance and margin strength in Danaos’s shipping portfolio. Next, we’ll examine how this earnings outperformance,...
NYSE:MYE
NYSE:MYEPackaging

Myers Industries (MYE) Following Strong Q2 Results, Is The Valuation Case Still Intact?

Myers Industries (MYE) stock is in focus after the company reported second quarter 2026 results, with higher sales, net income and earnings per share compared with the same period a year earlier. See our latest analysis for Myers Industries. The strong quarterly update and the amended loan agreement appear to have fed into a sharp repricing of Myers Industries, with a 90 day share price return of 77.32% and a 1 year total shareholder return of 138.19% that indicates momentum building rather...
NasdaqGS:AVGO
NasdaqGS:AVGOSemiconductor

Broadcom (AVGO) Lands At The Center Of Google’s Anthropic AI Hardware Push

Google has set up a multibillion dollar financing program for Anthropic that is focused on AI hardware. The program highlights Broadcom's role as a primary AI chip supplier within Anthropic's infrastructure plans. The initiative involves major Wall Street financing partners and is described as one of the largest AI hardware funding efforts to date. This move points to a deeper commitment from Google to AI infrastructure that sits alongside, and beyond, existing Broadcom contracts. For...
NasdaqGM:PAHC
NasdaqGM:PAHCPharmaceuticals

Is Phibro Animal Health (PAHC) Undervalued On Its Dividend Update?

Phibro Animal Health (PAHC) has confirmed a quarterly cash dividend of $0.12 per share on both its Class A and Class B stock. The payment is scheduled for September 23, 2026. See our latest analysis for Phibro Animal Health. Phibro Animal Health shares last closed at US$37.15, with a 1 month share price return of 11.7% but a 3 month share price return that declined 36.5%. Even so, the 1 year total shareholder return of 41.47% and 3 year total shareholder return of 160.59% indicate strong...